You are here

Novo Nordisk

Novo Nordisk extends innovative drug delivery research tie-up with MIT and BWH

Biopharma Reporter

Wed, 03/9/22 - 10:58 am

Brigham and Women's

Novo makes a rare disease push

EP Vantage

Wed, 03/9/22 - 10:42 am

Novo Nordisk, citing strong Wegovy demand, doubles 2025 sales target for obesity franchise

Fierce Pharma

Thu, 03/3/22 - 10:54 am

Novo Nordisk gets NICE okay for obesity drug Wegovy

Pharmaforum

Tue, 02/8/22 - 09:55 am

Novo Nordisk's Wegovy, hamstrung by Catalent FDA write-up, could correct course by mid-2022: analysts

Fierce Pharma

Thu, 01/27/22 - 10:47 am

Inside the Catalent FDA citation said to trigger Novo Nordisk's Wegovy supply hiccup

Fierce Pharma

Tue, 01/18/22 - 10:49 am

Novo Nordisk comes out clean in $1.8B investor lawsuit alleging insulin misdirection

Fierce Pharma

Mon, 01/17/22 - 10:55 am

Novo Nordisk moves to strengthen obesity efforts

Pharmaforum

Mon, 01/17/22 - 10:27 am

EraCal Therapeutics

Biotech investors pray for a takeover miracle

EP Vantage

Fri, 01/14/22 - 11:09 am

Amylyx Pharmaceuticals

Arena Pharmaceuticals

Aurinia Pharmaceuticals

Bristol Myers Squibb

Biopharma’s stock market winners of 2021 revealed

EP Vantage

Wed, 01/12/22 - 10:50 am

Moderna Therapeutics

Bicycle Therapeutics

Novo Nordisk's weight loss drug Wegovy to run short amid contract manufacturer hiccup

Fierce Pharma

Mon, 12/20/21 - 10:50 am

drug manufacturing

Novo Nordisk, underway with key launches, reveals $2.58B manufacturing investment

Fierce Pharma

Mon, 12/13/21 - 11:50 pm

drug manufacturing

Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China's latest cost squeeze

Fierce Pharma

Mon, 11/29/21 - 10:55 pm

China’s insulin plans will hit 2022 revenues, says Novo Nordisk

Pharmaforum

Fri, 11/26/21 - 08:54 pm

value-based procurement

Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna

Fierce Biotech

Thu, 11/18/21 - 10:54 am

Dicerna Pharmaceuticals

Novo Nordisk nears EU approval of obesity drug Wegovy

Pharmaforum

Fri, 11/12/21 - 10:34 am

Mixed court decisions for Novartis in DC and Sanofi, Novo Nordisk in NJ further complicate whose interpretation of 340B is correct

Endpoints

Mon, 11/8/21 - 10:46 am

Demand for new obesity drug outstripping supply

Beckers Hospital Review

Wed, 11/3/21 - 11:29 pm

Judge rules HHS' letter enforcing 340B discounts was 'arbitrary'

Beckers Hospital Review

Tue, 11/2/21 - 11:51 pm

United Therapeutics

Pages